Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Molecular and clinical analyses of 84 patients with tuberous sclerosis complex

  • Chia-Cheng Hung1,
  • Yi-Ning Su2, 10,
  • Shu-Chin Chien3,
  • Horng-Huei Liou4, 5,
  • Chih-Chuan Chen4,
  • Pau-Chung Chen6,
  • Chia-Jung Hsieh6,
  • Chih-Ping Chen7,
  • Wang-Tso Lee8,
  • Win-Li Lin1 and
  • Chien-Nan Lee9Email author
Contributed equally
BMC Medical Genetics20067:72

https://doi.org/10.1186/1471-2350-7-72

Received: 28 February 2006

Accepted: 18 September 2006

Published: 18 September 2006

Abstract

Background

Tuberous sclerosis complex (TSC) is an autosomal dominant disease characterized by the development of multiple hamartomas in many internal organs. Mutations in either one of 2 genes, TSC1 and TSC2, have been attributed to the development of TSC. More than two-thirds of TSC patients are sporadic cases, and a wide variety of mutations in the coding region of the TSC1 and TSC2 genes have been reported.

Methods

Mutational analysis of TSC1 and TSC2 genes was performed in 84 Taiwanese TSC families using denaturing high-performance liquid chromatography (DHPLC) and direct sequencing.

Results

Mutations were identified in a total of 64 (76 %) cases, including 9 TSC1 mutations (7 sporadic and 2 familial cases) and 55 TSC2 mutations (47 sporadic and 8 familial cases). Thirty-one of the 64 mutations found have not been described previously. The phenotype association is consistent with findings from other large studies, showing that disease resulting from mutations to TSC1 is less severe than disease due to TSC2 mutation.

Conclusion

This study provides a representative picture of the distribution of mutations of the TSC1 and TSC2 genes in clinically ascertained TSC cases in the Taiwanese population. Although nearly half of the mutations identified were novel, the kinds and distribution of mutation were not different in this population compared to that seen in larger European and American studies.

Background

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder having an incidence of 1 in 6,000 to 1 in 10,000 live births [1]. The severity of TSC and its impact on the quality of life are extremely variable among patients [2]. Common clinical manifestations of this disease include intellectual handicap, autistic disorders, and epilepsy due to the frequent, widespread occurrence of cortical tubers, which are focal disruptions of the cortical architecture due to undifferentiated giant cells. Hamartomas are also found in multiple other organ systems, including the heart, lungs, kidneys, and skin [3].

Patients often seek medical attention for dermal lesions or frequent seizures. The clinical diagnostic guidelines on TSC were prepared based on clinical features, radiographic findings, and histopathological findings [3]. Accurate clinical diagnoses are relatively easy in patients with classic multisystem involvement, but are often difficult due to the diversity of clinical findings in TSC patients.

The genetic basis of TSC has been determined to be due to mutation in either one of two unlinked genes, TSC1 and TSC2 [4]. The human TSC1 gene on chromosome 9q34 consists of 23 exons giving an 8.6-kb mRNA transcript, which has a coding region of 3.5-kb and encodes a 130-kDa protein spanning 1164 amino acids [5]. The TSC2 gene, which is located on chromosome 16p13.3, contains 41 exons and encodes a 200-kDa protein with 1807 amino acid [4, 6]. Both TSC1 and TSC2 are tumor suppressor genes and their protein products, hamartin and tuberin, respectively, form a complex that regulates the mammalian target of rapamycin (mTOR) in the phosphoinositide 3-kinases (PI3-kinase)/AKT pathway to control cellular proliferation, adhesion, growth, differentiation or migration [7, 8]. Furthermore, both genes play a role in cortical differentiation and growth control.

The mutation spectra of the TSC genes are very heterogeneous and no hotspots for mutations have been reported. There are many mutations in each gene that are seen recurrently, but no single mutation accounts for more than about 1% of all TSC patients. TSC2 mutations are about five times more common than TSC1 mutations [9] and new mutations are typically found in the two-thirds of TSC cases that are sporadic [10]. Despite complete penetrance of the disease in TSC patients, phenotypic variability can make the determination of disease status difficult among family members of affected individuals.

In this study, we analyzed both TSC1 and TSC2 genes in 84 independent Taiwanese TSC probands for whom detailed information on clinical manifestations and phenotype were available. Furthermore, we also assessed the mutational distribution and possible genotype-phenotype correlations between and within the two genes.

Methods

Patient Population

This study was approved by the Ethics Committee of the Division of Obstetrics and Gynecology, National Taiwan University Hospital. Eighty-four unrelated patients with confirmed clinical diagnoses of TSC and their family members were tested for mutations in TSC1 and TSC2 genes.

The general clinical features of TSC patients were determined by clinicians in accordance with the TSC diagnosis criteria set forth by the Tuberous Sclerosis Consensus Conference [3]. All patients' symptoms were investigated by a person blind to mutational status. High-resolution brain magnetic-resonance imaging (MRI) or computed tomography (CT) was performed on most patients.

The extent of facial angiofibroma or forehead plaques, non-traumatic ungal or periungal fibromas, hypomelanotic macules, shagreen patches, multiple retinal nodular hamartomas, cortical tubers, subependymal nodules, subependymal giant cell astrocytomas, cardiac rhabdomyomas, lymphangiomyomatoses, renal angiomyolipomas and confetti-like lesions were all assessed. Moreover, most patients' medical histories of mental development were assessed by a certified psychologist.

Sample Preparation

After genetic counseling and obtaining informed consent, 5–10 mL of peripheral blood were collected from the participants. Genomic DNA was isolated from peripheral whole blood using the Puregene DNA Isolation Kit (Gentra Systems, Inc., Minneapolis, MN, USA).

Mutational Analysis of TSCGenes

PCR primers and running conditions for each exon were available from previous studies [1113]. The PCR reaction was run on each exon with a total sample volume of 25 μL containing 100 ng of genomic DNA, 0.12 μM of each respective primer, 100 μM dNTPs, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl2, and 0.5 units of AmpliTaq Gold enzyme (PE Applied Biosystems, Foster City, CA, USA). Amplification was performed in a multiblock system thermocycler (ThermoHybaid, Ashford, UK). The PCR amplification started with a denaturing step at 95°C for 5 minutes, followed by 35 cycles of denaturing at 94°C for 30 seconds, annealing at melting temperature (Tm) for 30 seconds, extension at 72°C for 45 seconds, and ends with a final extension step at 72°C for 10 minutes.

The screening of mutations was performed using the Transgenomic Wave Nucleic Acid Fragment Analysis System (Transgenomic Inc, San Jose, CA) with a C18 reversed-phase column containing 2-μm nonporous poly (styrene/divinylbenzene) particles (DNASep Column, Transgenomic Inc). PCR products were analyzed using linear acetonitrile gradients and triethylammonium acetate acting as mobile phases with the provision of buffer A (0.1 M TEAA) and buffer B (0.1 M TEAA with 25% acetonitrile) (WAVE Optimized, Transgenomic Inc). Heteroduplex analyses were performed according to the manufacturer's protocol and of previous studies [14, 15].

Statistical method

The χ2 and Fisher exact tests were used to examine the differences in clinical manifestations, phenotypes, and mutation distributions in independent Taiwanese probands between patients with TSC1 and TSC2 genes.

Direct Sequence Analysis

PCR products were purified by solid-phase extraction and bidirectionally sequenced using Applied Biosystems' Taq DyeDeoxy terminator cycle sequencing kit (Applied Biosystems). Sequencing reactions were separated on a PE Biosystems 373A/3100 sequencer.

Results and Discussion

Identification and Characterization of Mutations

In the current study, we performed mutational analysis on the coding exons and the exon/intron junctions of both TSC1 and TSC2 in a total of 84 individuals with TSC and their family members. The determination of mutation vs. polymorphism was done by: 1) checking the mutation tables at the Chromium site (http://chromium.liacs.nl/); 2) comparison of findings to those of 100 healthy Taiwanese controls; and 3) checking the families similarly.

Nine mutations were identified in the TSC1 gene while 55 were identified in the TSC2 gene. Mutations in the TSC1 gene included five nonsense mutations with early termination codons and four insertions/deletions which caused frameshifts and resulted in premature truncation of the protein. Three of these mutations were novel, while six were previously reported (Table 1).
Table 1

Status of TSC1 mutations in Taiwanese patients with TSC

No.

Gene

Exon

Nucleotide change

Codon change

Mutation type

Inheritance

Reported

Reference

62

TSC1

7

c.602_604del CCT

 

In-frame deletion

S

N

This study

61

TSC1

15

c.1525C>T

p.R509X

Nonsense

F

R

[5]

72

TSC1

15

c.1791_1792dupAA

 

Frameshift

S

N

This study

2

TSC1

15

c.1884_1887delAAAG

 

Frameshift

F

R

[5]

36

TSC1

15

c.1959dupA

 

Frameshift

S

R

LOVD*

54

TSC1

17

c.2074C>T

p.R692X

Nonsense

S

R

[5]

31

TSC1

18

c.2283C>A

p.Y761X

Nonsense

S

R

[24]

3

TSC1

18

c.2332C>T

p.Q778X

Nonsense

S

N

This study

41

TSC1

18

c.2356C>T

p.R786X

Nonsense

S

R

[5]

Total: 9, F:2, S:7, N:3, R:6 MM:0, NM:5, FM:4, SM:0.

F: familial case, S:sporadic case.

N: non-reported, R: reported.

MM: missense mutations, NM: nonsense mutations, FM: frameshift/in-frame mutations, SM: splicing site mutations.

* The the Leiden Open (source) Variation Database which was available at http://chromium.liacs.nl/lovd/

The 55 mutations in the TSC2 gene included 12 missense, 15 nonsense, 21 frameshifts due to insertions and deletions and 7 putative splice-site mutations. Twenty-seven of these mutations were previously reported while 28 were novel (Table 2). Of the familial TSC2 missense mutations, A1141T and R1793Q may be rare polymorphic variants co-segregating with TSC. There was no direct evidence that these familial TSC2 missense mutational changes were pathogenic.
Table 2

Status of TSC2 mutations in Taiwanese patients with TSC

No.

Gene

Exon

Nucleotide change

Codon change

Mutation type

Inheritance

Reported

Reference

21

TSC2

1

c.109dupG

 

Frameshift

F

N

This study

30

TSC2

1

c.133_136delCTGA

 

Frameshift

S

R

DK*

35

TSC2

3

c.268C>T

p.Q90X

Nonsense

S

R

[25]

47

TSC2

6

c.632delC

 

Frameshift

S

N

This study

8

TSC2

intron 8

c.848+3delG

 

Splicing

S

N

This study

37

TSC2

9

c.856A>G

p.M286V

Missense

F

R

[10]

78

TSC2

10

c.1060C>T

p.Q354X

Nonsense

S

N

This study

75

TSC2

10

c.1117C>T

p.Q373X

Nonsense

S

R

DK*

48

TSC2

11

c.1226_1230delAACTG

 

Frameshift

S

N

This study

12

TSC2

12

c.1336C>T

p.Q446X

Nonsense

S

R

[25]

20

TSC2

14

c.1513C>T

p.R505X

Nonsense

S

R

[10]

57

TSC2

14

c.1513C>T

p.R505X

Nonsense

S

R

[10]

65

TSC2

intron 14

c.1599+2T>C

 

Splicing

S

N

This study

76

TSC2

16

c.1794C>G

p.Y598X

Nonsense

S

R

[10]

29

TSC2

16

c.1832G>A

R611Q

Missense

S

R

[10]

59

TSC2

intron 16

c.1840-2A>T

 

Spilicing

S

N

This study

82

TSC2

17

c.1939G>A

p.D647N

Missense

S

R

[26]

7

TSC2

18

c.2086T>C

p.C696R

Missense

S

R

[27]

53

TSC2

19

c.2103_2105dupTGA

 

In-frame insertion

S

N

This study

5

TSC2

19

c.2210T>C

p.L737P

Missense

S

N

This study

23

TSC2

20

c.2251C>T

p.R751X

Nonsense

S

R

[10]

70

TSC2

20

c.2251C>T

p.R751X

Nonsense

S

R

[10]

39

TSC2

21

c.2404dupA

 

Frameshift

F

N

This study

32

TSC2

21

c.2461A>T

p.K821X

Nonsense

S

N

This study

11

TSC2

21

c.2538delC

 

Frameshift

F

N

This study

67

TSC2

intron 21

c.2546-2A>T

 

Splicing

S

N

This study

73

TSC2

intron 22

c.2639+1G>C

 

Splicing

S

R

[9]

22

TSC2

23

c.2641delT

 

Frameshift

F

N

This study

27

TSC2

24

c.2824G>T

p.Q942X

Nonsense

S

N

This study

64

TSC2

26

c.2974C>T

p.Q992X

Nonsense

S

R

[28]

80

TSC2

26

c.3076dupT

 

Frameshift

S

N

This study

33

TSC2

28

c.3389delC

 

Frameshift

S

N

This study

19

TSC2

29

c.3412C>T

p.R1138X

Nonsense

S

R

[9]

42

TSC2

29

c.3421G>A

p.A1141T

Missense

F

N

This study

13

TSC2

30

c.3693_3696delGTCT

 

Frameshift

S

R

DK*

51

TSC2

30

c.3696dupT

 

Frameshift

S

N

This study

9

TSC2

33

c.4175_4176delAG

 

Frameshift

S

N

This study

26

TSC2

33

c.4440dupA

 

Frameshift

S

N

This study

77

TSC2

34

c.4541_4544delCAAA

 

Frameshift

S

R

[12]

18

TSC2

35

c.4603_4605delGAC

 

In-frame deletion

S

N

This study

34

TSC2

35

c.4603G>T

p.D1535Y

Missense

S

N

This study

83

TSC2

36

c.4830G>A

p.W1610X

Nonsense

S

R

DK*

28

TSC2

36

c.4846C>T

p.Q1616X

Nonsense

S

N

This study

16

TSC2

37

c.4909_4910delAA

 

Frameshift

S

N

This study

81

TSC2

38

c.5032dupT

 

Frameshift

S

N

This study

60

TSC2

39

c.5150T>C

p.L1717P

Missense

S

R

[29]

55

TSC2

intron 39

c.5160+3G>C

 

Splicing

S

N

This study

43

TSC2

intron 39

c.5160+4A>G

 

Splicing

S

R

[29]

4

TSC2

40

c.5227C>T

p.R1743W

Missense

S

R

DK *

50

TSC2

40

c.5227C>T

p.R1743W

Missense

S

R

DK*

56

TSC2

40

c.5228G>A

p.R1743Q

Missense

F

R

[30]

10

TSC2

40

c.5238_5255del18

 

Frameshift

S

R

[31]

25

TSC2

40

c.5238_5255del18

 

Frameshift

S

R

[31]

6

TSC2

40

c.5252_5259+19del27

 

Frameshift

S

R

[9]

15

TSC2

41

c.5378G>A

p.R1793Q

Missense

F

N

This study

Total: 55, F:8, S:47, N:28, R:27 MM:12, NM:15, FM:21, SM:7.

F: familial case, S:sporadic case.

N: non-reported, R: reported.

MM: missense mutations, NM: nonsense mutations, FM: frameshift/in-frame mutations, SM: splicing site mutations.

* The database of Dr David Kwiatkowski which was available at http://tsc-project.partners.org/

For both genes, sequence variants that were possible mutations were tested in all other family members, including the parents and both the affected and the unaffected family members. In total, 31 of the 64 mutations (48%) had not been reported elsewhere. Moreover, no mutational hotspots were identified in either gene, with only four different mutations being found twice in TSC2.

Compared with those of European and American counterparts [9, 10, 16], the distribution of the TSC1 and TSC2 mutations among Taiwanese population is similar. Therefore, the spectrum of mutations seen among the Taiwanese is no different in comparison to those already reported thus far for these two genes, based on the genetic analyses of European and American TSC patients using the Fisher exact test (P = 0.85, 0.46, and 0.14, respectively).

Identification and Characterization of Polymorphism

In order to identify whether the observed changes were mutations or polymorphisms, samples from 100 normal individuals serving as controls were analyzed. Changes that were not found in more than 200 control alleles were considered pathogenic. Therefore, unique or less frequent changes such as missense and splicing site mutations (Table 2) were considered likely pathogenic mutations. The nonpathogenic TSC1 and TSC2 mutations identified in the Taiwanese TSC patients are described in Table 3. We identified nine nonpathogenic polymorphisms in the TSC1 gene and 12 in the TSC2 gene. The nonpathogenic sequence variants were identified in both the TSC patients and the normal controls. Fourteen of these polymorphisms had not been reported previously (4 at the TSC1 locus and 10 at the TSC2 locus) that included one missense variant within the TSC1 coding region.
Table 3

Polymorphisms identified for TSC1 and TSC2 in Taiwanese TSC population.

TSC1

Exon

Nucleotide change

Codon change

Polymorphism type

Frequency

Reported

Reference

Intron 3

c.106+15

 

Intron

13 (16 %)

N

This study

10

c.965 T>C

p.M322T

Missense

9 (11%)

R

[24]

Intron 11

c.1142-33 A>G

 

Intron

9 (11%)

R

LOVDa

Intron 12

c.1264-12 T>C

 

Intron

3 (4 %)

N

This study

Intron 14

c.1437-37 C>T

 

Intron

9 (11%)

R

LOVDa

15

c.1726 T>C

p.L576L

Silent

11 (13 %)

N

This study

15

c.1960 C>G

p.Q654E

Missense

3 (4 %)

N

This study

Intron 18

c.2392-35 T>C

 

Intron

9 (11%)

R

[24]

22

c.2829 C>T

p.A943A

Silent

3 (4 %)

R

[24]

TSC2

Exon

Nucleotide change

Codon change

Polymorphism type

Frequency

Reported

Reference

14

c.1593 C>T

p.I531I

Silent

3 (4 %)

R

[26]

Intron 15

c.1717-30 G>A

 

Intron

2 (2 %)

N

This study

Intron 15

c.1717-27 G>A

 

Intron

1 (1 %)

N

This study

Intron 21

c.2545+45 T>A

 

Intron

11 (13 %)

N

This study

23

c.2652 C>T

p.Y884Y

Silent

1 (1 %)

N

This study

26

c.3126 G>T

p.P1042P

Silent

1 (1 %)

R

DKb

Intron 27

c.3285-19 C>T

 

Intron

1 (1 %)

N

This study

29

c.3475 C>T

p.R1159R

Silent

1 (1 %)

N

This study

33

c.4047 G>A

p.A1349A

Silent

2 (2 %)

N

This study

Intron 33

c.4493+18 G>A

 

Intron

1 (1 %)

N

This study

Intron 38

c.5069-21 G>A

 

Intron

1 (1 %)

N

This study

Intron 39

c.5161-9 C>T

 

Intron

7 (8 %)

N

This study

* Frequence means the number of cases in 84 Taiwanese TSC patients.

a The the Leiden Open (source) Variation Database which was available at http://chromium.liacs.nl/lovd/

b The database of Dr David Kwiatkowski which was available at http://tsc-project.partners.org/

Genotype-Phenotype Correlation: Familial or Sporadic TSC mutations

Mutations were identified and located in exons of both TSC1 and TSC2 genes (see Figure 1 and 2). Of the 64 mutations found, nine and 55 were associated with TSC1 (14%) and TSC2 (86%), respectively, as shown in Table 4. Of the 10 familial cases, 2 (20%) and 8 (80%) were TSC1and TSC2 mutations, respectively. Among the 54 sporadic cases, 7 TSC1 (13%) and 47 TSC2 (87%) mutations were found. Accordingly, there was no significant difference between sporadic and familial TSC cases with respect to the frequency of TSC1 vs TSC2 mutation (P = 0.62).
Figure 1

Diagram depicting the locations of mutations in the TSC1 gene. Nonsense (red), missense (blue), frameshift/in-frame (green) and splicing site (purple) mutations were identified.

Figure 2

Diagram depicting the locations of mutations in the TSC2 gene. Nonsense (red), missense (blue), frameshift/in-frame (green) and splicing site (purple) mutations were identified.

Table 4

Distribution of TSC1 and TSC2 mutations.

 

N

MM

NM

FM

SM

Total

TSC1mutaions

      

Familial

2

0

1

1

0

2 (3 %)

Sporadic

7

0

4

3

0

7 (11 %)

Total

9

0 (0 %)

5 (8 %)

4 (6 %)

0 (0 %)

9 (14 %)

TSC2 mutations

      

Familial

8

4

0

4

0

8 (13 %)

Sporadic

47

8

15

17

7

47 (73 %)

Total

55

12 (19 %)

15 (23 %)

21 (33 %)

7 (11 %)

55 (86 %)

N: screening numbers.

MM: missense mutations.

NM: nonsense mutations.

FM: frameshift/in-frame mutations.

SM: splicing site mutations.

Genotype-Phenotype Correlation: Clinical Manifestations

The clinical characteristics associated with each mutation in the proband are shown in Tables 5 (eight TSC1 mutations) and Table 6 (43 TSC2 mutations). Most patients with TSC1 and TSC2 mutations had seizures, brain lesions (subependymal nodules and/or cortical tubers detected by MRI), and dermal manifestations. Our criteria for intellectual disability included any degree of mental retardation and learning disorder. The incidence of intellectual disability appeared lower in patients with TSC1 mutations (3/8 = 38%) compared to that of patients with TSC2 mutations (27/43 = 63%). However, this difference was not statistically significant (P = 0.25), but this would be expected because of such small sample sizes. Similarly, the incidence of mental retardation in patients with TSC1 mutations (1/8 = 13%) appeared to be less than that of patients with TSC2 mutations (17/43 = 40%), but this difference was not statistically significant (P = 0.23). Similarly, the frequencies of renal findings, cortical tubers, subependymal giant cell astrocytomas, liver tumors, cardiac tumors, or skin manifestations, including hypomelanotic macules, facial angiofibromas, shagreen patches, and ungual fibromas did not significantly differ between the patients with TSC1 and TSC2 mutations. However, all of these comparisons are under-powered due to the relatively small number of patients with TSC1 mutations that were studied. For nearly all of the clinical features studied, the frequencies were less for those bearing TSC1 mutations than for those bearing TSC2 mutations. This is consistent with findings from other large studies, showing that TSC1 disease is less severe than TSC2 disease [9, 10, 16].
Table 5

Clinical data of patients with TSC1 mutations

Family no.

Familial/Sporadic

Mutation type

Sex

Onset age of seizure

Intellectual performance

Brain tubers

Renal tumors

Hepatic tumors

Cardiac rhabdomyoma

Hypomelanotic macules

Facial angiofibroma

Shagreen patch

Ungual fibroma

2

F

FS

F

2 y

N

+

0

NA

NA

0

+

0

+

3

S

NM

M

8 y 3 m

N

+

0

0

0

+

+

+

0

41

S

NM

F

1 y

N

+

0

0

+

+

0

0

0

31

S

NM

F

6 m

LD

+

+

0

+

+

0

0

0

36

S

FS

M

2 y

N

+

0

0

0

+

+

0

0

61

F

NM

M

3 y 6 m

LD

+

0

0

0

+

+

0

0

62

S

FS

M

1 m

LD

+

+

0

0

+

+

+

+

72

S

FS

M

3 y

N

+

0

0

+

+

0

+

0

N: normal or no seizure, LD: learning disorder, MR: metal retardation, NA: not available.

Table 6

Clinical data of patients with TSC2 mutations

Family no.

Familial/Sporadic

Mutation type

Sex

Onset age of seizure

Intellectual performance

Brain tubers

Renal tumors

Hepatic tumors

Cardiac rhabdomyoma

Hypomelanotic macules

Facial angiofibroma

Shagreen patch

Ungual fibroma

4

S

MM

M

10 m

N

+

+

0

0

+

+

+

0

5

S

MM

F

1 y

N

+

NA

NA

0

+

+

0

0

6

S

FS

M

1 m

LD

+

0

0

+

+

0

0

0

7

S

MM

M

6 m

MR

NA

NA

NA

NA

+

+

0

0

8

S

S

F

3 m

LD

+

+

0

0

+

+

+

0

9

S

FS

M

5 y

LD

+

0

0

0

+

+

+

0

10

S

FS

F

6 m

LD

+

0

0

+

+

+

0

0

11

F

FS

F

4 m

LD

+

+

0

+

0

+

+

0

12

S

NM

M

10 m

N

+

+

0

NA

+

+

+

0

13

S

FS

F

4 m

MR

+

NA

NA

+

0

0

0

0

15

F

MM

F

7 m

MR

+

0

0

0

+

0

0

0

16

S

FS

M

1 y

N

+

+

3

NA

+

+

+

+

18

S

FS

F

5 m

LD

+

NA

NA

NA

+

+

+

0

19

S

NM

M

3 m

MR

+

+

0

NA

+

0

0

0

20

S

NM

M

1 y 6 m

N

+

+

0

0

+

+

0

0

21

F

FS

F

9 y

N

+

+

1

0

+

+

+

+

22

F

FS

M

1 y

LD

NA

NA

NA

NA

+

+

+

0

23

S

NM

F

7 m

MR

+

NA

NA

NA

+

0

0

0

25

S

FS

M

6 m

LD

+

0

NA

0

+

+

+

0

26

S

FS

F

8 m

LD

+

+

0

0

+

+

+

0

27

S

NM

M

1 y

MR

+

+

0

0

+

+

0

0

28

S

NM

M

3 m

LD

+

NA

NA

NA

+

+

+

0

29

S

MM

F

6 m

MR

+

0

NA

0

+

0

+

0

30

S

FS

F

1 y

MR

+

+

0

0

+

+

0

0

32

S

NM

M

3 m

N

+

+

+

0

+

+

0

0

33

S

FS

F

1 m

N

+

+

+

0

+

+

+

+

34

S

MM

F

7 y

N

+

+

0

0

+

0

+

0

35

S

NM

M

1 y

MR

+

+

0

+

+

+

+

0

37

F

MM

M

9 m

MR

+

0

0

+

+

+

+

0

39

F

FS

F

3 m

MR

+

NA

NA

NA

+

+

+

0

42

F

MM

M

7 y

N

0

+

+

NA

+

+

+

+

47

S

FS

F

2 m

N

+

0

0

+

+

0

0

0

48

S

FS

F

3 m

MR

+

+

0

0

+

+

+

0

50

S

MM

M

3 m

MR

+

NA

NA

NA

+

+

+

0

53

S

FS

M

3 y

MR

+

+

0

0

+

+

+

0

56

F

MM

F

2 y

N

+

+

+

0

+

+

+

+

57

S

NM

F

6 m

MR

+

0

0

0

+

+

+

0

59

S

S

F

1 m

MR

+

+

0

0

+

+

0

0

64

S

NM

M

2 m

N

+

0

0

0

+

0

0

0

67

S

S

F

3 m

MR

+

0

0

+

+

+

0

0

73

S

S

F

21 y

N

+

0

0

0

+

+

0

+

75

S

NM

F

1 y

N

+

+

0

0

+

+

0

0

82

S

MM

M

1 m

N

0

0

0

+

0

0

0

0

N: normal or no seizure, LD: learning disorder, MR: metal retardation, NA: not available.

Conclusion

This study is the first analysis of TSC1 and TSC2 genes in the Taiwanese population. We identified 64 mutations among a total of 84 patients (76%); 9 were TSC1 mutations (14%) and 55 were TSC2 mutations (86%). These numbers are similar to other studies with larger cohorts [9, 10, 1618] and would be expected if the germ line mutation rate at the TSC2 locus were higher than that at the TSC1 locus. The failure to detect mutations in the remaining 24% of the patients may be due to a combination of lack of screening for large genomic deletion and rearrangement mutations in either TSC1 or TSC2. The occurrence of mosaic mutations [19, 20] in some of these patients that may be difficult to detect. Another reason is mutation detection failure.

According to previous reports, somatic and general mosaicism are seen in 6%-10% of all TSC patients [20, 21]. In addition, large deletions have been identified in about 2%-4% of TSC2 mutations [6] and less commonly in the TSC1 gene [22, 23]. Thus, both of these situations likely contributed to patients in which mutations were not identified.

In summary, sixty-four different mutations were identified and characterized for the Taiwanese population. Of those, 31 were not previously described. The diverse mutation spectrum of TSC was also seen in different families and different populations.

Notes

Abbreviations

DHPLC: 

Denaturing high performance liquid chromatography

TSC: 

Tuberous sclerosis complex

CT: 

Computed tomography

MRI: 

Magnetic-resonance imaging

PCR: 

Polymerase chain reaction

Tm: 

Melting temperature

Declarations

Acknowledgements

The authors gratefully extend their gratitude to the families and patients affected by TSC for their participation and cooperation in this study. We thank Prof. David Kwiatkowski, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School for deeply review and rewrite the manuscript. We thank Dr. Fon-Jou Hsieh for his expertise and assistance. This work was supported by a grant from the National Science Council of Taiwan (NSC 92-2314-B-002-319).

Authors’ Affiliations

(1)
Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University
(2)
Department of Medical Genetics, National Taiwan University Hospital
(3)
Departments of Medical Genetics and Obstetrics and Gynecology, China Medical University Hospital
(4)
Department of Neurology, National Taiwan University Hospital
(5)
Department of Pharmacology, College of Medicine, National Taiwan University
(6)
Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health
(7)
Department of Obstetrics and Gynecology, Mackay Memorial Hospital
(8)
Department of Pediatrics, National Taiwan University Hospital
(9)
Department of Obstetrics and Gynecology, National Taiwan University Hospital
(10)
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University

References

  1. Osborne JP, Fryer A, Webb D: Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991, 615: 125-127.View ArticlePubMedGoogle Scholar
  2. Gomez MR SJRHWV: Tuberous sclerosis complex. 3rd edn New York: Oxford University Press. 1999Google Scholar
  3. Roach ES, Gomez MR, Northrup H: Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998, 13 (12): 624-628.View ArticlePubMedGoogle Scholar
  4. Povey S, Burley MW, Attwood J, Benham F, Hunt D, Jeremiah SJ, Franklin D, Gillett G, Malas S, Robson EB, et al: Two loci for tuberous sclerosis: one on 9q34 and one on 16p13. Ann Hum Genet. 1994, 58 (Pt 2): 107-127.View ArticleGoogle Scholar
  5. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP, Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali JB, Ward S, Green AJ, Yates JR, Kwiatkowska J, Henske EP, Short MP, Haines JH, Jozwiak S, Kwiatkowski DJ: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997, 277 (5327): 805-808. 10.1126/science.277.5327.805.View ArticlePubMedGoogle Scholar
  6. The European Chromosome 16 Tuberous Sclerosis Consortium.: Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium. Cell. 1993, 75 (7): 1305-1315.View ArticleGoogle Scholar
  7. Astrinidis A, Henske EP: Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 2005, 24 (50): 7475-7481. 10.1038/sj.onc.1209090.View ArticlePubMedGoogle Scholar
  8. Kwiatkowski DJ, Manning BD: Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet. 2005, 14 Spec No. 2: R251-8. 10.1093/hmg/ddi260.View ArticlePubMedGoogle Scholar
  9. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ: Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001, 68 (1): 64-80. 10.1086/316951.View ArticlePubMedGoogle Scholar
  10. Jones AC, Shyamsundar MM, Thomas MW, Maynard J, Idziaszczyk S, Tomkins S, Sampson JR, Cheadle JP: Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999, 64 (5): 1305-1315. 10.1086/302381.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Jones AC, Daniells CE, Snell RG, Tachataki M, Idziaszczyk SA, Krawczak M, Sampson JR, Cheadle JP: Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet. 1997, 6 (12): 2155-2161. 10.1093/hmg/6.12.2155.View ArticlePubMedGoogle Scholar
  12. Maheshwar MM, Cheadle JP, Jones AC, Myring J, Fryer AE, Harris PC, Sampson JR: The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum Mol Genet. 1997, 6 (11): 1991-1996. 10.1093/hmg/6.11.1991.View ArticlePubMedGoogle Scholar
  13. Maheshwar MM, Sandford R, Nellist M, Cheadle JP, Sgotto B, Vaudin M, Sampson JR: Comparative analysis and genomic structure of the tuberous sclerosis 2 (TSC2) gene in human and pufferfish. Hum Mol Genet. 1996, 5 (1): 131-137. 10.1093/hmg/5.1.131.View ArticlePubMedGoogle Scholar
  14. Su YN, Lee CN, Hung CC, Chen CA, Cheng WF, Tsao PN, Yu CL, Hsieh FJ: Rapid detection of beta-globin gene (HBB) mutations coupling heteroduplex and primer-extension analysis by DHPLC. Hum Mutat. 2003, 22 (4): 326-336. 10.1002/humu.10265.View ArticlePubMedGoogle Scholar
  15. Xiao W, Oefner PJ: Denaturing high-performance liquid chromatography: A review. Hum Mutat. 2001, 17 (6): 439-474. 10.1002/humu.1130.View ArticlePubMedGoogle Scholar
  16. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A: Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005, 13 (6): 731-741. 10.1038/sj.ejhg.5201402.View ArticlePubMedGoogle Scholar
  17. Lewis JC, Thomas HV, Murphy KC, Sampson JR: Genotype and psychological phenotype in tuberous sclerosis. J Med Genet. 2004, 41 (3): 203-207. 10.1136/jmg.2003.012757.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Jones AC, Sampson JR, Hoogendoorn B, Cohen D, Cheadle JP: Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis. Hum Genet. 2000, 106 (6): 663-668. 10.1007/s004390050040.View ArticlePubMedGoogle Scholar
  19. Kwiatkowska J, Wigowska-Sowinska J, Napierala D, Slomski R, Kwiatkowski DJ: Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis. N Engl J Med. 1999, 340 (9): 703-707. 10.1056/NEJM199903043400905.View ArticlePubMedGoogle Scholar
  20. Sampson JR, Maheshwar MM, Aspinwall R, Thompson P, Cheadle JP, Ravine D, Roy S, Haan E, Bernstein J, Harris PC: Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet. 1997, 61 (4): 843-851.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Verhoef S, Bakker L, Tempelaars AM, Hesseling-Janssen AL, Mazurczak T, Jozwiak S, Fois A, Bartalini G, Zonnenberg BA, van Essen AJ, Lindhout D, Halley DJ, van den Ouweland AM: High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet. 1999, 64 (6): 1632-1637. 10.1086/302412.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Nellist M, Sancak O, Goedbloed MA, van Veghel-Plandsoen M, Maat-Kievit A, Lindhout D, Eussen BH, de Klein A, Halley DJ, van den Ouweland AM: Large deletion at the TSC1 locus in a family with tuberous sclerosis complex. Genet Test. 2005, 9 (3): 226-230. 10.1089/gte.2005.9.226.View ArticlePubMedGoogle Scholar
  23. Longa L, Saluto A, Brusco A, Polidoro S, Padovan S, Allavena A, Carbonara C, Grosso E, Migone N: TSC1 and TSC2 deletions differ in size, preference for recombinatorial sequences, and location within the gene. Hum Genet. 2001, 108 (2): 156-166. 10.1007/s004390100460.View ArticlePubMedGoogle Scholar
  24. Dabora SL, Sigalas I, Hall F, Eng C, Vijg J, Kwiatkowski DJ: Comprehensive mutation analysis of TSC1 using two-dimensional DNA electrophoresis with DGGE. Ann Hum Genet. 1998, 62 ( Pt 6): 491-504. 10.1046/j.1469-1809.1998.6260491.x.View ArticleGoogle Scholar
  25. Choy YS, Dabora SL, Hall F, Ramesh V, Niida Y, Franz D, Kasprzyk-Obara J, Reeve MP, Kwiatkowski DJ: Superiority of denaturing high performance liquid chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2. Ann Hum Genet. 1999, 63 ( Pt 5): 383-391. 10.1046/j.1469-1809.1999.6350383.x.View ArticleGoogle Scholar
  26. Zhang H, Nanba E, Yamamoto T, Ninomiya H, Ohno K, Mizuguchi M, Takeshita K: Mutational analysis of TSC1 and TSC2 genes in Japanese patients with tuberous sclerosis complex. J Hum Genet. 1999, 44 (6): 391-396. 10.1007/s100380050185.View ArticlePubMedGoogle Scholar
  27. Roberts PS, Ramesh V, Dabora S, Kwiatkowski DJ: A 34 bp deletion within TSC2 is a rare polymorphism, not a pathogenic mutation. Ann Hum Genet. 2003, 67 (Pt 6): 495-503. 10.1046/j.1529-8817.2003.00059.x.View ArticlePubMedGoogle Scholar
  28. Beauchamp RL, Banwell A, McNamara P, Jacobsen M, Higgins E, Northrup H, Short P, Sims K, Ozelius L, Ramesh V: Exon scanning of the entire TSC2 gene for germline mutations in 40 unrelated patients with tuberous sclerosis. Hum Mutat. 1998, 12 (6): 408-416. 10.1002/(SICI)1098-1004(1998)12:6<408::AID-HUMU7>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
  29. Chen CP, Su YN, Hung CC, Lee CN, Hsieh FJ, Chang TY, Chen MR, Wang W: Molecular genetic analysis of the TSC genes in two families with prenatally diagnosed rhabdomyomas. Prenat Diagn. 2005, 25 (2): 176-178. 10.1002/pd.1085.View ArticlePubMedGoogle Scholar
  30. Ichikawa T, Wakisaka A, Daido S, Takao S, Tamiya T, Date I, Koizumi S, Niida Y: A case of solitary subependymal giant cell astrocytoma: two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism. J Mol Diagn. 2005, 7 (4): 544-549.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Niida Y, Lawrence-Smith N, Banwell A, Hammer E, Lewis J, Beauchamp RL, Sims K, Ramesh V, Ozelius L: Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Hum Mutat. 1999, 14 (5): 412-422. 10.1002/(SICI)1098-1004(199911)14:5<412::AID-HUMU7>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
  32. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/7/72/prepub

Copyright

© Hung et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.